The FDA has given accelerated approval to oxaliplatin (Eloxatin, Sanofi-Synthelabo Inc, New York), a new antineoplastic agent with antitumor activity that differs from cisplatin and carboplatin. The drug is indicated for use as an injection in combination with infusional 5-fluorouracil and leucovorin (5-FU/LV) for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following first-line therapy with bolus 5-FU/LV plus irinotecan.
Crawford, Jr LM. Drug for Colorectal Cancer. JAMA. 2002;288(10):1225. doi:10.1001/jama.288.10.1225
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: